Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: Effects on vascular calcification, bone and a close look into the survival data

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Frazão, João M ^a,c   Adragão, Teresa ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SANTA CRUZ   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Hyperphosphatemia; Severelamer hydrochloride; Survival; Vascular calcification

Indexed keywords

CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; SEVELAMER;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DISEASE; BONE MINERALIZATION; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DYSPEPSIA; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MORBIDITY; MORTALITY; NAUSEA; OSSIFICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL; TRABECULAR BONE; TREATMENT DURATION; VOMITING;

BONE DISEASES; CALCINOSIS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; POLYAMINES; RENAL DIALYSIS; SURVIVAL ANALYSIS; VASCULAR DISEASES;

EID: 57049173903     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.544     Document Type: Conference Paper

References (32)

1. Guerin A, London G, Marchais S et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
3. London GM, Guérin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephol Dial Transplant 2003; 18: 1731-1740.
4. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
5. Block G, Hulbert-Shearon T, Levin N et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
7. Blacher J, Guérin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
8. Adragão T, Pires A, Lucas C et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-1488.
9. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701.
10. Spiegel DM, Raggi P, Metha R et al. Coronary and aortic calcification in patients new to dialysis. Hemodialysis Int 2004; 8: 265-272.
11. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
12. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-S201.
13. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
14. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401.
15. Moe SM, O'Neill KD, Fineberg N et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18: 1152-1158.
16. Belasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodalysis patients. Kidney Int 2006; 70: 16.
17. Adragao T, Pires A, Lucas C et al. Vascular and valvular calcifications in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 21: 281-285.
18. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score is a predictor of pulse wave velocity in hemodialysis patients. J Am Soc Nephrol 2005; 16: 473A (PO638).
19. Ferreira A, Frazão JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412.
20. Adragao T, Ferreira A, Frazão JM et al. Vascular Calcifications and bone turnover in hemodialysis patients. Nephrol Dial Transp 2006; 21(Suppl 4): iv 292 (MO014).
21. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
22. Asci G, Ozkahya M, Duman S et al. The link between cardiovascular and bone disease in hemodialysis patients. Nephrol Dial Transp 2007; 22(Suppl 6): vi 217 (MO014).
23. London GM, Marchais SJ, Gérin AP et al. Association of bone activity, calcium load, aortic sitfness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
24. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
25. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
26. U.S. Renal Data System, USRDS 2005 Annual Data Report National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005.
27. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.
28. Sadek T, Mazouz H, Bahloul H et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18: 582-589.
29. Shaheen FA, Akeel NM, Badawi LS et al. Efficacy and safety of sevelamer. Comparison with calciumcarbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25: 785-791.
30. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution. Nat Clin Pract nephrol 2008; 4: 115.
31. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2961.
32. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.